巨生醫 (6827.TW) 2025Q2 financial report shows operating profit of -63.76M TWD, with a YoY growth rate of 27.76%, clearly higher than last year, reflecting solid business operations and good profit flexibility. It is recommended to also monitor the structure of operating profit, recent revenue, and gross margin, and compare with peers, using Growin AI Value Analysis to confirm whether the growth is supported by fundamentals. If the company can maintain this steady growth, it is commendable.